Article Sidebar
Published:
Oct 3, 2018DOI:
10.4314/tjpr.v17i9.3Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Formulation development and optimization of orally disintegrating tablets of montelukast sodium by Design- Expert
Abstract
Purpose: To prepare orally disintegrating tablets (ODT) of montelukast sodium using Design-Expert for improved patient compliance.
Methods: Central composite design was selected to delineate and optimize the formulations. Concentrations of crospovidone (X1) and sodium bicarbonate (X2) were selected as the variables, and responses were based on friability (Y1) and disintegration time (Y2). Varying amounts of super disintegrating agents and effervescent bases were used with microcrystalline cellulose to prepare montelukast sodium ODT.
Results: Carr’s index of montelukast sodium was 4.76±0.075, indicating the good compressibility of powder. Whereas the Carr’s value for microcrystalline cellulose and mannitol were 30.14±0.021 and 22.41±0.053 respectively. The FTIR spectra indicated that there were no major shifting and loss of functional groups in drug and excipients blends. Formulations were evaluated, check point batch (CPB, F2) was selected using Design-Expert. The friability of CPB tablets was found to be 0.27 ± 0.085; hardness, 4.96 ± 0.093 kp; wetting time, 28 ± 0.17 s; disintegration time (DT), 28.34 ± 1.78 s; and drug release, 85.5 % within 5 min.
Conclusion: The ODT of montelukast sodium has successfully been formulated by direct compression and optimized within a short period, thus demonstrating the suitability and stability of the formulation.
Keywords: Direct compression, Montelukast sodium, Orally disintegrating tablets, Super-disintegrants, Design Expert, Crospovidone
